Analysts Anticipate Entera Bio Ltd. (NASDAQ:ENTX) to Post -$0.10 Earnings Per Share

Wall Street analysts predict that Entera Bio Ltd. (NASDAQ:ENTX) will report ($0.10) earnings per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Entera Bio’s earnings. Entera Bio reported earnings per share of ($0.09) in the same quarter last year, which would suggest a negative year over year growth rate of 11.1%. The firm is scheduled to announce its next quarterly earnings results on Thursday, November 18th.

On average, analysts expect that Entera Bio will report full year earnings of ($0.85) per share for the current year, with EPS estimates ranging from ($0.91) to ($0.78). For the next financial year, analysts forecast that the business will report earnings of ($0.59) per share, with EPS estimates ranging from ($0.61) to ($0.56). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Entera Bio.

Entera Bio (NASDAQ:ENTX) last issued its earnings results on Sunday, August 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.09). The company had revenue of $0.11 million for the quarter. Entera Bio had a negative net margin of 3,414.71% and a negative return on equity of 161.80%.

A number of research firms have recently issued reports on ENTX. B. Riley boosted their target price on Entera Bio from $9.00 to $14.00 and gave the company a “buy” rating in a report on Thursday, June 24th. Aegis reissued a “buy” rating and issued a $12.00 price target on shares of Entera Bio in a research note on Monday, July 12th. Finally, Zacks Investment Research downgraded Entera Bio from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 19th.

A number of institutional investors have recently bought and sold shares of the business. XTX Topco Ltd bought a new position in Entera Bio in the first quarter worth approximately $44,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Entera Bio during the second quarter worth about $86,000. Geode Capital Management LLC purchased a new position in Entera Bio in the second quarter valued at approximately $105,000. Millennium Management LLC purchased a new position in Entera Bio in the 1st quarter valued at $147,000. Finally, Renaissance Technologies LLC raised its stake in shares of Entera Bio by 66.8% during the 1st quarter. Renaissance Technologies LLC now owns 120,407 shares of the company’s stock worth $459,000 after buying an additional 48,221 shares during the last quarter. 21.57% of the stock is owned by institutional investors and hedge funds.

ENTX stock traded down $0.10 during midday trading on Thursday, reaching $5.11. The stock had a trading volume of 858 shares, compared to its average volume of 4,083,872. The company’s fifty day simple moving average is $5.01 and its 200 day simple moving average is $4.43. The company has a market cap of $121.11 million, a price-to-earnings ratio of -5.98 and a beta of 1.67. Entera Bio has a 52-week low of $1.01 and a 52-week high of $10.16.

About Entera Bio

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of orally delivered large molecule therapeutics. It develops an oral formulation of parathyroid hormone. The company was founded on June 1, 2010 and is headquartered in Jerusalem, Israel.

Further Reading: How Important is Technical Analysis of Stocks

Get a free copy of the Zacks research report on Entera Bio (ENTX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with's FREE daily email newsletter.